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Purpose: Sorafenib is an effective systemic agent for advanced hepatocellular car-
cinoma. To increase its efficacy, we evaluated the feasibility and benefit of 
sorafenib combined with radiotherapy. Materials and Methods: From July 2007 
to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and 
radiotherapy. Among them, 13 patients who received radiotherapy on the bone 
metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on 
the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the mea-
surable metastatic lesions (measurable metastasis group). Tumor responses at 1 
month after the completion of radiotherapy and overall survival were evaluated. 
Results: The in-field response rate was 100% in the primary group and 60% in the 
measurable metastasis group. A decrease of more than 80% in the tumor marker 
α-fetoprotein was observed in 7 patients in the primary group (54%). Toxicities of 
grades 3-4 were hand-foot syndrome in 3 (17%) patients, duodenal bleeding in 1 
(6%) patient, thrombocytopenia in 3 (17%) patients and elevation of aspartate 
transaminase in 1 (6%) patient. The median overall survival was 7.8 months (95% 
confidence interval, 3.0-12.6). Conclusion: The combined treatment of sorafenib 
and radiotherapy was feasible and induced substantial tumor responses in the tar-
get lesions. The results of this study emphasize the importance of individualized 
approach in the management of advanced hepatocellular carcinoma and encourage 
the initiation of a controlled clinical trial.
Key Words:   Hepatocellular carcinoma, combined modality therapy, radiotherapy, 
sorafenib
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy world-
wide.1 The incidence is also increasing, not only in Asia by hepatitis B viral infec-
tion, but also in the United States, Europe, and Japan by hepatitis C infection.2,3 In 
addition, liver cirrhosis due to alcoholic liver disease and/or genetic problems also 
poses a risk of HCC.4,5 However, approximately 70% of patients are diagnosed 
with advanced stage diseases, and treatment options for them are very limited.6 
Sorafenib (Nexavar, Bayer HealthCare Pharmaceutics, Leverkusen, Germany-
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studies of these patients were retrospectively reviewed. Af-
ter the review, 13 patients who received RT on the bone 
metastasis were excluded, and remaining 18 patients were 
analyzed.
Diagnosis of HCC was based on either histologic proof 
(6 patients) or clinicoradiological criteria under the practice 
guidelines of the Korean Liver Cancer Study Group (12 pa-
tients).19 
Patients were divided into two groups according to the 
site of RT: the primary group for primary liver lesions (13 
patients), and the measurable metastasis group for mass 
forming measurable metastatic lesions (5 patients). Treat-
ment decisions were made through discussion at multidis-
ciplinary conference of liver cancer special clinic. Every 
patient received full explanation of the discussion. General 
inclusion criteria of primary group were 1) locally ad-
vanced stage; 2) unable to perform intra-arterial chemo-
therapy because of tumor thrombosis or vessel invasion; 
and 3) patients with metastasis but the tumor burden could 
be covered by radiation or main tumor burden was inside 
or near the liver. General inclusion criteria of measurable 
metastasis group were 1) recurred with measurable metas-
tasis which could be covered by RT; and 2) liver was can-
cer-free. 
Table 1 shows the clinical features of the patients. The 
median age of the patients was 53 years. Each patient’s 
stage was determined using the Japanese Tumor-Node-Me-
tastasis system.20 Eighty-three percent of the patients had 
chronic viral hepatitis. Only one patient (6%) had stage III 
HCC, 8 patients (44%) had stage IVA, and 9 patients (50%) 
stage IVB. Before the combined treatment, 12 patients (67%) 
received other treatments. All of them received local treat-
ment to liver, including surgical resection, radiofrequency 
ablation, transarterial chemoembolization and RT. Two pa-
tients (11%) received systemic chemotherapy. 
Radiotherapy 
In the primary group, 12 of the 13 patients received RT us-
ing 3-dimensional conformal RT (3D CRT). For the remain-
ing patient, RT was targeted to the liver lesion, metastatic 
lesions and distant lymph nodes, and treatment was per-
formed by helical tomotherapy. The total radiation dose 
ranged from 30 to 54 Gy (median, 45 Gy). 
In the measurable metastasis group, there were lymph 
node metastases in 3 patients, seeding nodules in the pelvic 
cavity in 1 patient, and a chest wall mass in 1 patient. Two 
patients with lymph node metastasis received 58.42 Gy 
Onyx Pharmaceuticals, South San Francisco California, CA, 
USA) is an oral multi-kinase inhibitor that blocks the serine-
threonine kinase Raf-1 and the activity of receptor tyrosine 
kinases of vascular endothelial growth factor receptors,7,8 
which are key mediators in the molecular pathogenesis of 
HCC.9-12 It has shown survival benefit in advanced HCC 
patients through randomized phase III trials.13,14 A meta-
analysis of randomized controlled trials confirmed signifi-
cant prolongation of time to progression by 79% and an in-
crease in overall survival by 37.3%.15 Based on this evidence, 
sorafenib has been the first and the only systemic agent for 
advanced HCC. However, there are not many studies that 
have investigated the use of combined treatment modalities 
to enhance the efficacy of sorafenib. 
Radiotherapy (RT) is one of possible candidates. The Na-
tional Comprehensive Cancer Network Guidelines version 
2.2012 of HCC recommends RT as a locoregional therapy 
for all tumors irrespective of location.16 In addition, there 
are several studies revealing good responses and feasibili-
ties of combining RT with other treatment modalities.17,18 
The antiangiogenic effects of sorafenib may contribute to 
escalating the radiosensitivity of the tumor by improving 
tumor oxygenation. In addition, the antiproliferative effects 
of sorafenib may delay disease progression outside the radi-
ation field. On the other hand, RT to the target lesion can 
enhance overall response rates (ORR) in patients treated 
with sorafenib by reducing local tumor burden.
Based on these rationales, a combined treatment of 
sorafenib and RT may be a novel therapeutic strategy with 
stronger antitumor effects. Until now, the clinical experi-
ence using this combined treatment has been limited. In this 
study, we aimed to evaluate feasibility of combined treat-
ment of sorafenib and RT in locally advanced or metastatic 
HCC. Also, we examined the response and survival time to 
estimate the efficacy of the combined treatment.
MATERIALS AND METHODS
　　　
This study was approved by the Institutional Review Board 
of our institution (approval number: 4-2010-0761) and re-
vised for extension of the period to 2012. 
Patient characteristics
Between July 2007 and July 2011, 31 HCC patients were 
treated concurrently with sorafenib and RT. The medical re-
cords, results of laboratory tests, histology, and imaging 
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cc of the duodenum was limited to 45 Gy. 
Biologically effective dose (BED) was converted to con-
ventional fractionation schedule of each dose due to varia-
tion in dose fractionation schedule. The α/β ratio was 10. Af-
ter the conversion, the median dose of the primary group 
and the measurable metastasis group were 45 Gy and 50.4 
Gy, respectively. Table 2 summarizes dose fractionation 
schedules of groups. 
Sorafenib 
Sorafenib was administered twice a day with a total daily 
dose of 800 mg to 12 of 13 patients in the primary group, 
and 3 of 5 patients in the measurable metastasis group. The 
rest of the patients were treated with total daily dose of 400 
mg because of their recent history of systemic chemothera-
py prior to sorafenib or low baseline blood cell count. 
Sorafenib was administered concurrently with RT within 
one week of initial RT. 
Evaluation of treatment response and acute toxicities
In the primary group, treatment response and progression 
were evaluated 1 month after the completion of RT using the 
modified Response Evaluation Criteria in Solid Tumors (RE-
CIST).21 ORR was defined as partial response (PR) or com-
plete response (CR). The level of serum α-fetoprotein (AFP) 
was checked before and after the combined treatment. 
In the measurable metastasis group, their responses were 
evaluated between 1 and 3 months after the completion of 
RT using RECIST version 1.1.22 Criteria for determination 
of response were the same as above with a different defini-
tion for target lesions, which indicated whole lesions, but 
not contrast-enhancing lesions.
Overall survival (OS) rate and time to progression (TTP) 
were calculated from the day of RT initiation to the date of 
death and the date of progression, respectively, and were 
estimated by the Kaplan-Meier method. 
According to the Common Terminology Criteria for Ad-
verse Events v3.0, the development of toxicity was moni-
tored through physical examination and laboratory testing for 
the levels of blood cell counts and chemistry, both during 
treatment and after the completion of treatment. 
And, we divided patients according to the experience of 
dermatological adverse events during the RT including 
hand-foot skin reaction, erythema, and alopecia. The poten-
tial association between dermatological adverse events and 
efficacy was explored by comparing treatment response, 
OS, and TTP using chi-square test and log-rank test. 
with a daily dose of 2.54 Gy using helical tomotherapy. 
One patient with lymph node metastasis treated with 3D 
CRT received 50.4 Gy with 1.8 Gy daily. One patient with 
seeding nodules in the pelvic cavity received 39 Gy with 3 
Gy daily using 3D CRT. Chest wall metastasis was treated 
with a total dose of 30 Gy in 6 Gy daily fractions with heli-
cal tomotherapy. 
In patients treated with helical tomotherapy, the mean 
dose to the remaining liver volume, which is defined as the 
volume of the whole liver minus intrahepatic clinical target 
volume, was restricted to below 28 Gy, and the dose to the 2 
Table 1. Patient Characteristics (n=18)
Characteristics No. of patients (%)
Sex
    Male 17 (94)
    Female 1 (6)
ECOG Performance status
    0-1 15 (83)
    ≥2   3 (17)
Viral etiology
    B 14 (77)
    C 1 (6)
    Non-B, non-C   3 (17)
Child-Pugh classification*
    A 11 (85)
    B   2 (15)
AFP elevation (≥200 IU/mL)
    Yes 10 (56)
    No   8 (44)
Japanese TNM stage
    III 1 (6)
    IVA   8 (44)
    IVB   9 (50)
Previous treatment
    No   6 (33)
    Local therapy for liver tumor only† 10 (56)
    Systemic CTx only 0 (0)
    Both   2 (11)
ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; TNM, 
Tumor-Node-Metastasis; CTx, chemotherapy.
*Primary group only.
†Local therapy for liver tumor includes resection of the liver, radiofrequency 
ablation, transhepatic arterial chemoembolization and radiation therapy.
Table 2. Doses of Radiotherapy According to the Group (Gy)
Median (range) Primary (n=13)
Measurable 
metastasis (n=5)
Total dose  45 (30-54) 50.4 (30-58.42)
Fraction size 1.8 (1.8-5) 2.54 (1.8-6)
BED  45 (32.4-61.2) 50.4 (41.4-61.2)
BED, biologically effective dose.
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of size reduction rate for in-field target lesions was 61%. One 
patient showed CR of the target lesion inside of the radiation 
field, but out-field progression was observed on the 1-month 
follow-up imaging study (Fig. 1). Two patients showed lung 
metastasis on the 1-month follow-up CT. CT images of one 
patient are shown in Fig. 2. The mean serum AFP showed a 
decrease from the pre-treatment level of 8323±16837 IU/mL 
to the post-treatment level of 1501±2606 IU/mL. A decrease 
in AFP of more than 80% was observed in 7 patients (54%).
In patients who received RT for measurable metastasis, 
the ORR was 60%. Four patients (80%) showed a size re-
duction of the target lesions. Two patients (40%) had out-
RESULTS
 
Treatment response
Tumor response was evaluated by imaging studies in 11 pa-
tients in the primary group and 5 patients in the measurable 
metastasis group. Two patients in the primary group who 
did not undergo imaging study after the treatment under-
went follow-up of tumor markers only.
In the primary group, the size of target lesions was larger 
than 5 cm in all patients. The ORR of in-field target lesions 
by modified RECIST was 100% (Table 3). The mean value 
Table 3. Treatment Response in Primary Group According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) 
and RECIST (n=11)
No. of patients (%)
CR PR SD/non-PD* PD ORR
Modified RECIST
    In-field (target lesions) 1 (9) 10 (91) 0 (0) 0 (0) 11 (100)
    Out-field (non-target lesions)   7 (64) 4 (36)
    Total evaluation† 0 (0)   7 (64) 0 (0) 4 (36) 7 (64)
RECIST
    In-field (target lesions) 1 (9)   2 (18)   8 (73) 3 (27)
    Out-field (non-target lesions)   7 (64) 4 (36)
    Total evaluation† 0 (0)   2 (18)   5 (46) 4 (36) 2 (18)
CR, complete remission; PR, partial response; SD, stable disease; PD, progression of disease; ORR overall response rate.
*SD for in-field, non-PD for out-field.
†According to RECIST, determined by responses of both target lesions and non-target lesions.
Fig. 1. Illustrations of a patient in the primary group who achieved in-field CR but had out-field progression in the liver. (A) The pretreatment computed to-
mography (CT) scan shows two lesions. The lesion located in the segment 6 was treated with transarterial chemoembolization. (B) Axial dose distribution of 
3-D conformal radiotherapy (RT). The lesion in the segment 4 was treated with RT, and (C) 1 month after completion of RT, a follow-up CT scan shows disap-
pearance of the lesion in the segment 4. Unfortunately, the lesion in the segment 6 had progressed. CR, complete remission.
A
C
B
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rates of the primary group and the measurable metastasis 
group were 35% and 60%, respectively. 
Safety
The incidence and proportion of grades 3 and 4 adverse 
events are listed in Table 4. The most common toxicity was 
thrombocytopenia. Two patients showed grade 3 thrombo-
cytopenia, and 1 patient showed grade 4 thrombocytopenia. 
One of the two patients who showed grade 3 thrombocyto-
penia experienced gastrointestinal bleeding. The patient 
with grade 4 thrombocytopenia suffered from grade 3 duo-
denal hemorrhage requiring an endoscopic vigorous diag-
nostic approach. Due to the bleeding, the patient had to skip 
planned RT for a week. 
The second most common toxicity was hand-foot syn-
drome. Three patients experienced grade 3 hand-foot syn-
drome, and another 2 patients complained of scrotal hair 
loss, desquamation, and eczema. After dose reduction of 
sorafenib, the symptoms were resolved. There was no inter-
ruption of treatment due to adverse events affecting the skin.
In one patient, liver enzyme aspartate aminotransferase 
(AST) level was elevated to 215 IU/L, which was a grade 3 
side effect. The patient was asymptomatic, and the AST 
level was normalized after a week of conservative care. 
Overall, no treatment-related mortality was observed. 
Most patients tolerated the treatment well and were able 
to complete the planned treatment. Adverse events at post-
treatment 3 months and 6 months were checked to deter-
field progression on the 1-month follow-up imaging studies. 
Survival 
The median OS of all 18 patients was 7.8 months [95% 
confidence interval (CI), 3.0-12.6] and the 1 year-OS rate 
was 37%. 
The median OSs of the primary group and the measurable 
metastasis group were 7.8 months (95% CI, 6.1-9.5) and 
15.7 months (95% CI, 0-33.7), respectively. The 1 year-OS 
Fig. 2. Illustrations of a patient in the primary group who achieved in-field PR but showed progression of lung metastasis. (A) The pretreatment computed to-
mography (CT) scan shows a huge mass invading the right portal vein. Small metastatic nodules are seen in both lungs (arrows). (B) Axial dose distribution 
of 3-D conformal radiotherapy (RT), and (C) 1 month after completion of RT, a follow-up abdomen CT scan shows a decrease in size in the target lesion, but a 
chest CT scan shows new metastatic nodules in both lungs (arrows). PR, partial response.
A
C
B
Table 4. Adverse Events
Adverse event
No. of patients (%)
All grades Grade 3 Grade 4
Dermatological
    Hand-foot syndrome   6 (33)   3 (17) 0 (0)
    Other skin reaction   4 (22) 0 (0) 0 (0)
Gastrointestinal
    Nausea   5 (28) 0 (0) 0 (0)
    Vomiting   3 (17) 0 (0) 0 (0)
    Diarrhea   2 (11) 0 (0) 0 (0)
    Duodenal bleeding 1 (6) 1 (6) 0 (0)
    Hematochezia 1 (6) 0 (0) 0 (0)
Hematological
    Anemia 0 (0) 0 (0) 0 (0)
    Leukopenia   4 (22) 0 (0) 0 (0)
    Thrombocytopenia 12 (67)   2 (11) 1 (6)
Chemistry
    AST elevation   2 (11) 1 (6) 0 (0)
    ALT elevation   2 (11) 0 (0) 0 (0)
 AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Sorafenib with RT in Advanced HCC
Yonsei Med J   http://www.eymj.org   Volume 54   Number 5   September 2013 1183
apy before undergoing the combined treatment. The myelo-
suppressive effect of previous chemotherapy might have 
contributed to the higher incidence of thrombocytopenia, 
although the overall incidence of hematologic toxicities 
was within the acceptable range. Further studies are needed 
to investigate underlying mechanism of this phenomenon.
In the present study, two patients experienced gastroin-
testinal hemorrhage; one patient with grade 3 duodenal 
bleeding presented as melena and another patient with rec-
tal bleeding presented as hematochezia. 
A patient with grade 3 duodenal bleeding, who also pre-
sented with grade 4 thrombocytopenia, had received 3 cy-
cles of systemic 5-fluorouracil and carboplatin before the 
combination treatment. Her baseline platelet count before 
the combination treatment was 38000/μL and she received 
a reduced dose of sorafenib. Abdominal lymph node area 
was the radiation target, and she received 58.42 Gy with 
helical tomotherapy. After resting for one week with only 
conservative care, her duodenitis and melena were resolved, 
and she was able to complete the planned treatment. In the 
literature, the overall incidence of acute upper gastrointesti-
nal bleeding has been reported as 2-38% after RT for liver 
tumors, associated with inclusion of the whole circumfer-
ence of the hollow viscus in RT field, high radiation dose, 
and decreased hepatic function.26-28 In this patient, hepatic 
function was well preserved (Child-Pugh class A). Organs 
at risk were individually delineated and avoided as much as 
possible. Low platelet count as well as radiation enteritis 
might have contributed to duodenal bleeding, but the im-
pact of sorafenib on the upper gastrointestinal bleeding 
needs to be evaluated in a larger number of patients. Ac-
cording to a report on the dose-response relationship by 
Park, et al.,29 the incidence of gastrointestinal complication 
in patients receiving the same dose as our patient did (>50 
Gy) can be estimated as 13.2%.
In the patient with hematochezia, the radiation field was 
the pelvic cavity including seeding nodules as well as the 
rectum, and the total dose was 39 Gy in 3 Gy daily frac-
tionations, which was compatible to 48.6 Gy (α/β=3) in a 
conventional BED. The patient presented with grade 2 diar-
rhea and hematochezia. Mild radiation proctitis was con-
firmed by colonoscopy. Grade 3 thrombocytopenia accom-
panied without a history of previous chemotherapy. After 
supportive care for a week, the patient recovered and com-
pleted the treatment. Radiation-induced lower gastrointesti-
nal complication has been thoroughly investigated in an 
acute radiation proctitis model, occurring in 26.4-47% of 
mine the occurrence of mid- and long-term side effects. 
There were 4 cases of side effects that occurred 3 months 
after the treatment. In the primary group, 2 patients experi-
enced grade 1 radiation pneumonitis. Both of them had re-
ceived RT to the lesions in the liver dome. One patient ex-
perienced grade 1 gastrointestinal discomfort because of 
sorafenib. The patient who had received RT to the pelvic 
cavity experienced grade 2 radiation proctitis. No side ef-
fects from the combined treatment occurred 6 months after 
the completion of the combined treatment. 
Dermatological adverse events and treatment efficacy
Seven patients experienced dermatological adverse events 
and another 7 patients did not present any cutaneous symp-
tom during the RT. All 7 patients (100%) with dermatologi-
cal adverse events showed PR, while 4 of the 7 patients 
(57%) without the events gained PR (p=0.051). The medi-
an OS was 7.8 months (95% CI, 7.2-8.4) in the patients 
with dermatologic adverse events, versus 16.4 months 
(95% CI, 0-38.5) in the patients who did not develop the 
events (p=0.142). In terms of TTP, the results were 4.1 
months (95% CI, 2.1-6.1) versus 6.9 months (95% CI, 6.5-
7.3), without statistical significance (p=0.127).  
DISCUSSION
In this work, we studied adverse events and treatment re-
sponses of combined treatment of sorafenib and RT in 18 
patients. The ORR was 100% for the primary group and 
60% for the measurable metastasis group. The most com-
mon adverse event was thrombocytopenia. Two patients 
experienced gastrointestinal hemorrhage without treatment-
related mortality.
In randomized trials of sorafenib monotherapy, the inci-
dences of overall and grade 3-4 thrombocytopenia were 
46% and 4%, respectively, in the sorafenib group.14 Trials 
of RT on hepatic lesions combined with systemic or region-
al chemotherapeutic agents reported thrombocytopenia in 
18-49% of patients and grade 3-4 thrombocytopenia in 
6-12% of patients.23-25 In our present study, the incidence of 
overall thrombocytopenia was 67%, and that of grades 3-4 
was 17%. The slightly higher incidence rate in our study 
might be attributed to two factors: concurrent administra-
tion of sorafenib with RT and a history of previous system-
ic chemotherapy. Two of the 3 patients who experienced 
grades 3-4 thrombocytopenia received systemic chemother-
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well as another study in a sequential manner (ClinicalTri-
als.gov number, NCT00999843). 
In the combined treatment of sorafenib with RT, acute tox-
icities were manageable, no treatment-related mortality was 
observed, and a substantial tumor response was achieved in 
the target lesions. Despite its limitations, our experience 
emphasizes the importance of a multidisciplinary approach-
es and individualized medicine in the management of ad-
vanced HCC. Further elucidation of the mechanisms of in-
teraction between sorafenib and RT is also warranted.
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